Companies › Neurogene
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Neurology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NGN-401 Recombinant AAV9 carrying full-length human MECP2 transgene | MECP2 | Phase 3 | Rett Syndrome | Dec 2029 |
| NGN-101 Gene therapy for CLN5 deficiency delivered via intracerebroventricular and intravitreal in | CLN5 | Phase 1 | Neuronal Ceroid Lipofuscinosis CLN5 | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05228145 | NGN-101 | Phase 1 | Neuronal Ceroid Lipofuscinosis CLN5 | Metabolic and endocrine | Nov 2028 |
| NCT05898620 | NGN-401 | Phase 3 | Rett Syndrome | Neurology | Dec 2029 |
Cash and short-term investments of $360m on 2026-09-30; operating cash outflow about $106m a year; runway about 41 months at that burn, to Feb 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
REGENXBIO Taysha Gene Therapies AskBio Elpida Therapeutics SPC NeuroPace
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.